Henan University of Chinese Medicine, Zhengzhou, 450046 Henan, China.
Department of Nephropathy, Henan Provincial Hospital of Traditional Chinese Medicine/The Second Hospital Affiliated to Henan University of Chinese Medicine, Zhengzhou, 450002 Henan, China.
Biomed Res Int. 2021 Mar 23;2021:6657206. doi: 10.1155/2021/6657206. eCollection 2021.
The study is aimed at investigating the effects of Ginkgo biloba extract EGB761 on renal tubular damage and endoplasmic reticulum stress (ERS) in diabetic kidney disease (DKD). A total of 50 C57BL/6 N mice were randomly divided into the normal group, DKD group, DKD+EGB761 group (36 mg/kg), and DKD+4-phenylbutyrate (4-PBA) group (1 g/kg). The DKD model was replicated by high-fat diet combined with intraperitoneal injection of streptozotocin (STZ). Renal tubular epithelial cells (HK-2) were divided into the control group, high-glucose group (30 mmol/L), EGB761 group (40 mg/L, 20 mg/L, 10 mg/L), TM group, and TM+4-PBA group. After 8 weeks of administration, expressions of serum creatinine (Scr), blood urea nitrogen (BUN), 24 h urinary protein (24 h Pro), fasting blood glucose (FBG), -microglobulin ( -MG), and retinol binding protein 4 (RBP4) of mice were tested. The pathological changes of renal tissue were observed. The expressions of extracellular matrix (ECM) accumulation and epithelial-mesenchymal transition (EMT) markers -smooth muscle actin (-SMA), E-cadherin, fibronectin, and collagen IV, as well as the ERS markers GRP78 and ATF6, were tested by Western blot, qPCR, immunohistochemistry, or immunofluorescence. EGB761 could decrease the Scr, BUN, 24 h Pro, and FBG levels in the DKD group, alleviate renal pathological injury, decrease urine -MG, RBP4 levels, and decrease the expression of -SMA, collagen IV, fibronectin, and GRP78, as well as ATF6, while increase the expression of E-cadherin. These findings demonstrate that EGB761 can improve renal function, reduce tubular injury, and ameliorate ECM accumulation and EMT in DKD kidney tubules, and the mechanism may be related to the inhibition of ERS.
该研究旨在探讨银杏叶提取物 EGB761 对糖尿病肾病(DKD)肾小管损伤和内质网应激(ERS)的影响。将 50 只 C57BL/6N 小鼠随机分为正常组、DKD 组、DKD+EGB761 组(36mg/kg)和 DKD+4-苯丁酸(4-PBA)组(1g/kg)。通过高脂肪饮食联合腹腔注射链脲佐菌素(STZ)复制 DKD 模型。将肾小管上皮细胞(HK-2)分为对照组、高糖组(30mmol/L)、EGB761 组(40mg/L、20mg/L、10mg/L)、TM 组和 TM+4-PBA 组。给药 8 周后,检测各组小鼠血清肌酐(Scr)、血尿素氮(BUN)、24 小时尿蛋白(24 h Pro)、空腹血糖(FBG)、β2-微球蛋白(β2-MG)和视黄醇结合蛋白 4(RBP4)水平,观察肾脏组织病理变化。采用 Western blot、qPCR、免疫组化或免疫荧光法检测细胞外基质(ECM)积聚和上皮-间充质转化(EMT)标志物 -平滑肌肌动蛋白(-SMA)、E-钙黏蛋白、纤连蛋白和胶原 IV 以及 ERS 标志物葡萄糖调节蛋白 78(GRP78)和活化转录因子 6(ATF6)的表达。EGB761 可降低 DKD 组 Scr、BUN、24 h Pro 和 FBG 水平,减轻肾脏病理损伤,降低尿β2-MG、RBP4 水平,下调-SMA、胶原 IV、纤连蛋白和 GRP78、ATF6 的表达,上调 E-钙黏蛋白的表达。这些发现表明,EGB761 可改善 DKD 肾脏的肾功能,减轻肾小管损伤,并改善 DKD 肾小管 ECM 积聚和 EMT,其机制可能与抑制 ERS 有关。